Showing results (4211-4220 of 6,795) with videos related to
Sort By:
Pageof 680
Clinical Therapeutics|December 1, 2001
Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulationR Mofsen, J BalterClinical Therapeutics|August 17, 2002
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studiesMaria-Teresa Zanella, Artur B RibeiroClinical Therapeutics|August 17, 2002
Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infectionsAlicia D Bucko, Barbara J Hunt, Sarah L Kidd, et al.Clinical Therapeutics|August 17, 2002
Double-blind, placebo-controlled, dose-ranging study of ramosetron for the prevention of nausea and vomiting after thyroidectomyYoshitaka Fujii, Hiroyoshi TanakaClinical Therapeutics|August 17, 2002
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challengeBob Q Lanier, Mark B Abelson, William E Berger, et al.Clinical Therapeutics|June 27, 2000
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con OlanzapinaJ A Sacristán, J C Gómez, A L Montejo, et al.Clinical Therapeutics|June 27, 2000
Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapyO Ylikorkala, P Lim, P CaubelClinical Therapeutics|March 15, 2003
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) studyAnders G Olsson, Mats Eriksson, Owe Johnson, et al.Clinical Therapeutics|March 15, 2003
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed careCarolyn Harley, Samuel WagnerClinical Therapeutics|March 15, 2003
Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trialMaria De Jesus Moreno MorenoPageof 680